Literature DB >> 27135875

Evaluation of a genetic assay for canine transmissible venereal tumour diagnosis in Brazil.

K F Castro1, A Strakova2, M Tinucci-Costa1, E P Murchison2.   

Abstract

The canine transmissible venereal tumour (CTVT) is a transmissible cancer that is spread between dogs by the allogeneic transfer of living cancer cells. The infectious agents in CTVT are the living cancer cells themselves, which are transmitted between dogs during coitus. CTVT first arose several thousand years ago and the disease has a global distribution and is frequently observed in dogs from Brazil. We evaluated the utility of a LINE-MYC quantitative polymerase chain reaction for diagnosis of CTVT cases in Brazil. Our analysis indicated that the LINE-MYC rearrangement was detectable in all CTVT samples but not in their corresponding hosts. This genetic assay proves to be a useful tool for providing a definitive molecular diagnosis of CTVT, which presents with varying degrees of aggressiveness and invasiveness in different host dogs and can therefore be a diagnostic challenge in some specific cases.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  LINE-MYC; canine transmissible venereal tumour; molecular diagnosis; oncology; transmissible cancer

Mesh:

Substances:

Year:  2016        PMID: 27135875     DOI: 10.1111/vco.12205

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  2 in total

Review 1.  Doing more with less: multiple uses of a single slide in veterinary cytology. A practical approach.

Authors:  Carla Marrinhas; Fernanda Malhão; Célia Lopes; Filipe Sampaio; Raquel Moreira; Mario Caniatti; Marta Santos; Ricardo Marcos
Journal:  Vet Res Commun       Date:  2022-06-18       Impact factor: 2.816

2.  Computer tomographic imaging in 4 dogs with primary nasal canine transmissible venereal tumor and differing cellular phenotype.

Authors:  Javier Ojeda; Marcelo Mieres; Francisco Soto; Verónica Arnes; Enrique Paredes; María Navarrete
Journal:  J Vet Intern Med       Date:  2018-03-31       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.